Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

Launched by DONG-A ST CO., LTD. · Nov 21, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new medication called DA-5219 to see how well it works and how safe it is for people suffering from acute or chronic gastritis, which is inflammation of the stomach lining. The study is currently recruiting participants who are between 19 and 75 years old and have recently been diagnosed with gastritis through a procedure called upper gastrointestinal endoscopy. This test helps doctors see the inside of the stomach and can identify any erosions or damage.

If you or someone you know is interested in participating, it's important to know that participants will need to have given their consent and must not have certain other conditions, such as active ulcers or esophageal issues. Throughout the trial, participants can expect to receive the study medication and will be closely monitored by healthcare professionals for safety and effectiveness. This trial aims to provide valuable information that could help improve treatment options for gastritis in the future.

Gender

ALL

Eligibility criteria

• Main Inclusion Criteria:
• • Men or women aged ≥ 19 years and ≤ 75 years
• • Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization
• • Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization
• • Subjects who voluntarily signed a consent form
• Main Exclusion Criteria:
• • Ineligible for upper gastrointestinal endoscopy
• • Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization
• • Subjects with hypersensitivity to investigational drugs and similar drugs
• • Pregnant or breastfeeding women